Shandong Drafts 15th Five-Year Pharma Plan to Accelerate Antibody and Cell-Gene Therapies
Shandong Province has released a draft action plan for the 15th Five-Year Plan period to accelerate the development of innovative drugs, with an emphasis on antibody drugs and cell and gene therapies. The plan targets major infectious diseases, respiratory infections, malignant tumors, drug-resistant infections, autoimmune, metabolic, and central nervous system conditions. Key focuses include monoclonal antibodies, bispecific and trispecific antibodies, antibody-drug conjugates, recombinant proteins, cell and gene therapy, innovative vaccines, and marine biopharmaceuticals. It also supports advanced antibody platforms such as nanobodies, combined antibodies, high-concentration formulations, and next-generation ADCs to strengthen industrialization capacity.
The "Shandong Province Pharmaceutical Industry 15th Five-Year Development Action Plan (Draft for Comments)" has recently been released for public consultation. The plan proposes to focus on disease areas such as major infectious diseases, respiratory infections, malignant tumors, drug-resistant infections, autoimmune, metabolic, and central nervous system diseases, and accelerate the development of key directions including monoclonal antibody drugs, bispecific antibodies, trispecific antibodies, antibody-drug conjugates, recombinant proteins, cell and gene therapy drugs, innovative vaccines, and marine biopharmaceuticals. It aims to promote core technology breakthroughs and speed up industrialization.
In the field of antibody drugs, the plan specifies a focus on antibody drugs for the treatment of malignant tumors, blood diseases, autoimmune diseases, metabolic diseases, ophthalmic diseases, neurological disorders, cardiovascular diseases, and anti-infective diseases. At the same time, it supports the development of innovative technology platforms such as multifunctional antibody drugs, antibody fusion proteins, nanobodies, combined antibodies, antibody combination formulations, high-concentration formulations, and novel antibody-drug conjugates, to enhance industrialization capabilities.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Biotechnology, with intensity 75/100 and 70% confidence over a long term horizon.
Biotechnology
- Direction
- positive
- Intensity
- 75
- Confidence
- 70%
- Horizon
- Long term
Pharmaceuticals
- Direction
- positive
- Intensity
- 70
- Confidence
- 65%
- Horizon
- Long term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.